Arthur Tzianabos, Homology Medicines CEO
Oxford Biomedica enters the AAV manufacturing world, buying Homology's in-house business
Oxford Biomedica’s outgoing CEO is ending his tenure with somewhat of a bang.
The British company has secured a deal to launch a new US …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
